Renal Protection with Angiotensin Receptor Blockers

Introduction to ARB Therapy

The American College of Cardiology recommends losartan and irbesartan as the most kidney-friendly ARBs, with losartan being the only ARB with FDA-approved indication specifically for reducing hard renal endpoints in type 2 diabetic nephropathy, demonstrated in the landmark RENAAL trial 1

For diabetic nephropathy with macroalbuminuria, losartan is the preferred choice based on the RENAAL trial, which demonstrated a 16% reduction in the composite endpoint of doubling serum creatinine, ESRD, or death, with 25% reduction in sustained doubling of serum creatinine and 29% reduction in ESRD 2
Irbesartan is equally effective based on the IDNT trial, showing similar renoprotective efficacy in type 2 diabetic nephropathy with macroalbuminuria 2
Both ARBs demonstrated superiority over other antihypertensive classes in slowing GFR decline and preventing kidney failure 2

The American Heart Association recommends starting losartan 50 mg daily, titrate to 100 mg daily if blood pressure goal not achieved and medication is tolerated 1
The renoprotective effect is dose-dependent; higher doses provide greater protection against CKD progression 3

Enhance efficacy with thiazide or loop diuretics, as 60-90% of patients in major ARB trials used concomitant diuretics 1
Combination therapy provides complementary mechanisms for blood pressure reduction 4
Never combine ARB + ACE inhibitor, as it increases adverse events without mortality benefit, demonstrated in multiple trials 5, 6

Do not use ARBs in pregnancy, symptomatic hypotension, uncontrolled hyperkalemia, or bilateral renal artery stenosis 3, 4
ARBs are not recommended for patients without hypertension to prevent development of CKD, as trials showed no benefit in preventing diabetic glomerulopathy in normotensive patients without albuminuria 5, 6